Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.
Phillip Low, PhD
Advertisement
Articles by Phillip Low, PhD
CancerNetwork® spoke with Phillip Low, PhD, about the development and FDA approval of pafolacianine.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
2
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
3
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
4
Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma
5